Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria.

On February 18, 2020, CARB-X awarded a $16.9 million grant to Lytica Therapeutics for a project to “develop antibacterial peptides with broad activity against multidrug-resistant bacteria.”¹⁾

CARB-X is funded by the Bill & Melinda Gates Foundation, Biomedical Advanced Research and Development Authority (BARDA), German Federal Ministry of Education and Research, National Institute of Allergy and Infectious Diseases (NIAID), United Kingdom Department of Health and Social Care (through the Global Antimicrobial Resistance Innovation Fund), and the Wellcome Trust.²⁾

CARB-X's Global Accelerator Network is composed of:³⁾

• California Life Sciences
• Centre for Cellular and Molecular Platforms (C-CAMP)
• Foundation for Innovative New Diagnostics (FIND)
• German Center for Infectious Diseases (DZIF)
• Institute for Life Sciences Entrepreneurship (ILSE)
• RTI International